Oculis Charts Bold 2026 Path With Pipeline Milestones at Investor Conferences
Oculis announces March 2026 investor conference participation, showcasing pipeline advances including Privosegtor's optic neuritis breakthrough designation and anticipated Phase 3 readouts.
OCSOCSAWinvestor conferencesclinical trials